TCGA-XF-AAN7-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 18.56110381
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- G2M_CHECKPOINT+0.590
- MYC_TARGETS_V1+0.440
- MITOTIC_SPINDLE+0.410
- DNA_REPAIR+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.310
- UV_RESPONSE_DN+0.290
- HEDGEHOG_SIGNALING+0.250
- TGF_BETA_SIGNALING+0.240
- WNT_BETA_CATENIN_SIGNALING+0.230
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.330
- INFLAMMATORY_RESPONSE-0.330
- TNFA_SIGNALING_VIA_NFKB-0.310
- ESTROGEN_RESPONSE_LATE-0.290
- INTERFERON_GAMMA_RESPONSE-0.290
- IL6_JAK_STAT3_SIGNALING-0.270
- ALLOGRAFT_REJECTION-0.260
- CHOLESTEROL_HOMEOSTASIS-0.250
- INTERFERON_ALPHA_RESPONSE-0.250
- XENOBIOTIC_METABOLISM-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-6591-01A-11R-1755-07 | — | cohortMD1 | 0.870 |
| 2 | SRR934937 | — | — | 0.863 |
| 3 | MNG1018 | — | — | 0.851 |
| 4 | 961CEC20-67F2-4615-8725-F35C12F0BC9B | — | — | 0.851 |
| 5 | BS_Z7890YNR | EPN | Supratentorial EPN | 0.839 |
| 6 | TCGA-21-5783-01A-41R-2187-07 | — | cohortMD1 | 0.839 |
| 7 | CA366342-0949-4941-8AE6-984BAF032886 | — | — | 0.839 |
| 8 | SRR934744 | — | — | 0.838 |
| 9 | MNG257 | — | — | 0.837 |
| 10 | SRR934990 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.040 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.030 | Inavolisib | — uncovered |